TheStreet’s Jim Cramer answers viewers’ Twitter (TWTR) questions from the floor of the New York Stock Exchange. When a viewer asks if Biogen’s (BIIB) horseman has fallen off the horse, Cramer says he needs to reevaluate the company. Biogen, one of Cramer’s ‘Four Horsemen,’ disappointed investors by lowering its full-year earnings and sales forecast because it no longer expects its multiple sclerosis drug Tecfidera to grow as expected. While he reconsiders the stock, Cramer stresses that he likes Regeneron (REGN), Celgene (CELG) and Gilead (GILD) much more than Biogen here. Another viewer notes that Inotek Pharmaceuticals (ITEK) just had a positive phase two meeting with the U.S. Food and Drug Administration and asks if the stock is a buy here. Cramer explains that the smart money was already there before the company’s meeting with the FDA and that the stock would be too risky for him now. When it comes to Sprint (S), Cramer says the stock is a sell. He says it’s a balance sheet issue for Sprint and he believes the company needs to raise a lot of money. He also weighs in on other names in the space like T-Mobile (TMUS), AT&T (T) and Verizon (VZ). If you have a stock question, tweet it @jimcramer using #CramerQ.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
